Angion Biomedica Corp
1 day chart
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company’s products include ANG-3070, ROCK2 Inhibitor, CYP11B2 Inhibitor and ANG-3777. ANG-3070 is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. The Company provides ANG-3070 for Fibrotic Diseases; ANG-3070 for Renal Fibrosis; ANG-3070 for Pulmonary Fibrosis. ROCK2 Inhibitor program targeted towards the treatment of fibrotic diseases. CYP11B2 Inhibitor program targeted towards diseases related to aldosterone synthase dysregulation. ANG-3777 is designed to mimic the biological activity of HGF and to treat acute organ injuries, such as delayed graft function.
Buy US stocks in Australia with $0 brokerage and trade ANGN today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.